Published in J Clin Invest on March 12, 2012
TAZ expression as a prognostic indicator in colorectal cancer. PLoS One (2013) 1.55
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell (2016) 1.48
Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clin Cancer Res (2015) 1.42
Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26
Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J (2013) 1.22
Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS One (2013) 1.19
Versican and the control of inflammation. Matrix Biol (2014) 1.13
Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia (2012) 1.01
The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics (2014) 0.99
miR-155-deficient bone marrow promotes tumor metastasis. Mol Cancer Res (2013) 0.98
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest (2013) 0.97
TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood (2014) 0.97
Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol (2015) 0.94
Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. Cancer Microenviron (2014) 0.92
Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J (2014) 0.92
Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat (2014) 0.91
Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1. PLoS One (2014) 0.85
Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel) (2012) 0.85
A role for versican in the development of leiomyosarcoma. J Biol Chem (2014) 0.83
RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res (2014) 0.83
RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology (2012) 0.82
Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget (2016) 0.81
Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther (2013) 0.81
Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer. Int J Mol Sci (2015) 0.79
Inflammation and skeletal metastasis. Bonekey Rep (2015) 0.79
Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancer. Am J Transl Res (2015) 0.78
Upregulation of the B7/CD28 family member B7-H3 in bladder cancer. Oncol Lett (2014) 0.77
Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding. Neoplasia (2016) 0.77
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
Correlation of Versican Expression, Accumulation, and Degradation during Embryonic Development by Quantitative Immunohistochemistry. J Histochem Cytochem (2015) 0.76
Knockdown of versican V1 induces a severe inflammatory response in LPS-induced acute lung injury via the TLR2-NF-κB signaling pathway in C57BL/6J mice. Mol Med Rep (2016) 0.75
Versican deficiency significantly reduces lung inflammatory response induced by polyinosine-polycytidylic acid stimulation. J Biol Chem (2016) 0.75
Interplay of extracellular matrix and leukocytes in lung inflammation. Cell Immunol (2016) 0.75
Bladder cancer: New insight into the mechanisms of lung metastasis. Nat Rev Urol (2012) 0.75
Probing chromatin landscape reveals roles of endocardial TBX20 in septation. J Clin Invest (2016) 0.75
Protective Role of Rho Guanosine Diphosphate Dissociation Inhibitor, Ly-GDI, in Pulmonary Alveolitis. PLoS One (2015) 0.75
Provisional matrix: A role for versican and hyaluronan. Matrix Biol (2016) 0.75
Lentivirus-mediated knockdown of P27RF-Rho inhibits hepatocellular carcinoma cell growth. Contemp Oncol (Pozn) (2017) 0.75
Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget (2016) 0.75
Insights from animal models of bladder cancer: recent advances, challenges, and opportunities. Oncotarget (2017) 0.75
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95
Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet (2002) 3.82
Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res (2004) 3.76
Cancer: Inflaming metastasis. Nature (2009) 3.09
Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol (2002) 3.00
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 2.55
Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer (2010) 2.41
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis (2004) 2.35
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res (2007) 2.31
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell (2005) 1.85
The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest (2008) 1.85
CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain (2008) 1.85
Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem (2009) 1.81
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst (2010) 1.74
Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer (2009) 1.69
Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res (2004) 1.56
Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res (2008) 1.56
Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res (2009) 1.53
Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev (2010) 1.52
Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant (2009) 1.51
The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res (2005) 1.49
Extracellular matrix of the central nervous system: from neglect to challenge. Histochem Cell Biol (2008) 1.48
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res (2002) 1.36
Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol (2006) 1.34
Extracellular matrix changes in stented human coronary arteries. Circulation (2004) 1.32
Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A (2002) 1.32
Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol (2002) 1.27
ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis (2007) 1.22
Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol (2007) 1.22
Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem (2005) 1.21
Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res (2009) 1.21
Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol (2002) 1.20
Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res (2004) 1.20
Versican V0 and V1 guide migratory neural crest cells. J Biol Chem (2006) 1.19
A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem (1994) 1.19
Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A (2009) 1.17
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene (2006) 1.17
The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res (2007) 1.14
Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res (2007) 1.13
Erosive vitreoretinopathy and wagner disease are caused by intronic mutations in CSPG2/Versican that result in an imbalance of splice variants. Invest Ophthalmol Vis Sci (2006) 1.12
Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem (1994) 1.12
Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer (2010) 1.11
Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion. Am J Respir Cell Mol Biol (2009) 1.10
Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res (2008) 1.10
Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J Neurosci (2009) 1.03
SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia (2008) 1.01
SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia (2007) 1.01
V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab Invest (2006) 0.99
Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev (2009) 0.98
Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. Mol Cell Proteomics (2010) 0.96
Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol (1999) 0.96
Athsq1 is an atherosclerosis modifier locus with dramatic effects on lesion area and prominent accumulation of versican. Arterioscler Thromb Vasc Biol (2008) 0.95
Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J Biol Chem (2010) 0.95
Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology (2009) 0.93
V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J Cancer (2005) 0.92
Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J Biol Chem (2007) 0.91
Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem (2009) 0.89
Versican modulates gap junction intercellular communication. J Cell Physiol (2007) 0.89
Differential expression of versican isoforms is a component of the human melanoma cell differentiation process. Biochim Biophys Acta (2003) 0.89
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88
Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat (2010) 0.87
Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. Clin Exp Allergy (2005) 0.87
Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res (2003) 0.86
Versican V0 and V1 direct the growth of peripheral axons in the developing chick hindlimb. J Neurosci (2011) 0.86
Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma. Ann Surg Oncol (2011) 0.85
Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis (2006) 0.85
Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res (2010) 0.84
Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods (2009) 0.82
Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. J Investig Med (2007) 0.82
Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics (2007) 0.82
Altered expression of versican and hyaluronan in melanocytic tumors of dogs. Am J Vet Res (2007) 0.81
The origin of hyaluronectin in human tumors. Int J Cancer (1997) 0.79
Effect of transforming growth factor-beta1, insulin-like growth factor-I, and hepatocyte growth factor on proteoglycan production and regulation in canine melanoma cell lines. Am J Vet Res (2002) 0.77
Intracellular versican expression in mesenchymal spindle cell tumors contrasts with extracellular expression in epithelial and other tumors--a tissue microarray-based study. Appl Immunohistochem Mol Morphol (2008) 0.76
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Cancer incidence after localized therapy for prostate cancer. Cancer (2006) 2.52
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol (2008) 2.18
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
Profiling the evolution of human metastatic bladder cancer. Cancer Res (2004) 2.00
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res (2005) 1.89
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer (2002) 1.83
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A (2012) 1.79
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res (2006) 1.75
Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer (2009) 1.69
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol (2008) 1.65
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res (2007) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol (2011) 1.55
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res (2010) 1.54
Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol (2009) 1.53
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res (2009) 1.44
The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res (2006) 1.41
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res (2005) 1.41
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol (2011) 1.39
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res (2002) 1.31
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther (2007) 1.29
Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res (2008) 1.28
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res (2011) 1.28
Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One (2012) 1.23
Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res (2009) 1.21
PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene (2004) 1.20
Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A (2009) 1.17
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol (2010) 1.17
Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (2008) 1.16
CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res (2012) 1.16
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res (2010) 1.14
Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics (2011) 1.14
Angiogenesis and prostate cancer tumor growth. J Cell Biochem (2004) 1.13
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci (2012) 1.12
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol (2010) 1.12
Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg (2005) 1.10
Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol (2014) 1.08
Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett (2003) 1.08
Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.08
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics (2012) 1.08
Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol Cancer Ther (2007) 1.07
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol (2006) 1.06
Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology (2003) 1.06
RhoGDI signaling provides targets for cancer therapy. Eur J Cancer (2010) 1.06
Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res (2010) 1.05
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther (2009) 1.05
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Adrenal tumor with caval extension--case report and review of the literature. Scand J Urol Nephrol (2002) 1.04
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia (2009) 1.03
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol (2009) 1.01
Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med (2010) 1.00
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol (2009) 1.00
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res (2012) 1.00
RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia (2010) 0.98
Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev (2009) 0.98
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest (2013) 0.97
Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors. Oncol Nurs Forum (2007) 0.97
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
Haemangiomas in kidneys with end-stage renal disease: a novel clinicopathological association. Histopathology (2014) 0.96
Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem (2009) 0.95
RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol (2007) 0.95
Family interactions among African American prostate cancer survivors. Fam Community Health (2008) 0.95
Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum (2004) 0.95
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res (2013) 0.94
Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol (2014) 0.94